

A study to compare zoledronic acid and calcium and vitamin D, with placebo (dummy) and calcium and vitamin D, on the frequency of hip fractures and of new spinal fractures in post-menopausal women with osteoporosis

Submission date 12/09/2003	Recruitment status No longer recruiting	☐ Prospectively registered
Registration date 12/09/2003	Overall study status Completed	☐ Protocol
Last Edited 11/07/2014	Condition category Musculoskeletal Diseases	☐ Statistical analysis plan
		☒ Results
		☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr R Eastell

Contact details

Metabolic Bone Centre
Sorby Wing
Northern General Hospital
Herries Road
Sheffield
United Kingdom
S5 7AU
+44 0114 2714705
r.eastell@sheffield.ac.uk

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00049829

Protocol serial number

N0059115932

Study information

Scientific Title**Study objectives**

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

For the UK part of the trial, approved by North Sheffield Research Ethics Committee, reference NS02 1 1247, date of favourable opinion 21/03/02.

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Musculoskeletal Diseases: Osteoporosis

Interventions

Compare zoledronic acid and calcium and vitamin D, with placebo (dummy) and calcium and vitamin D.

Intervention Type

Supplement

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Zoledronic acid, calcium, vitamin D

Primary outcome(s)

Added 31 July 2008:

1. To assess the incidence of hip fractures in all patients treated with zoledronic acid compared to patients in the placebo group at 3 years

2. To assess the incidence of new vertebral fractures in patients treated with zoledronate acid compared to patients taking placebo at 3 years among patients not taking concomitant therapy for osteoporosis at baseline (stratum 1)

Key secondary outcome(s)

Added 31 July 2008:

1. Percent change in hip BMD as measured by DXA over 3 years
2. Proportion of patients in stratum 1 with new and/or worsening vertebral fractures at 1 year
3. Incidence of all clinical fractures in stratum 1 and 2 over 3 years

Completion date

30/06/2003

Eligibility

Key inclusion criteria

Post-menopausal women with osteoporosis.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/07/2002

Date of final enrolment

30/06/2003

Locations

Countries of recruitment

United Kingdom

England

Germany

United States of America

Study participating centre
Metabolic Bone Centre
Sheffield
United Kingdom
S5 7AU

Sponsor information

Organisation
Department of Health (UK)

Funder(s)

Funder type
Industry

Funder Name
Sheffield Teaching Hospitals (UK)

Funder Name
Novartis

Alternative Name(s)
Novartis AG, Novartis International AG

Funding Body Type
Government organisation

Funding Body Subtype
For-profit companies (industry)

Location
Switzerland

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	03/05/2007		Yes	No